A Phase IIa, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer

Trial Profile

A Phase IIa, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Oshadi D (Primary) ; Oshadi R (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Oshadi Drug Administration
  • Most Recent Events

    • 21 Apr 2015 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
    • 21 Apr 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
    • 02 Sep 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top